[go: up one dir, main page]

EA199800140A1 - Композиции с контролируемым высвобождением пароксетина - Google Patents

Композиции с контролируемым высвобождением пароксетина

Info

Publication number
EA199800140A1
EA199800140A1 EA199800140A EA199800140A EA199800140A1 EA 199800140 A1 EA199800140 A1 EA 199800140A1 EA 199800140 A EA199800140 A EA 199800140A EA 199800140 A EA199800140 A EA 199800140A EA 199800140 A1 EA199800140 A1 EA 199800140A1
Authority
EA
Eurasian Patent Office
Prior art keywords
controlled release
release compositions
paroxetine
paroxetine controlled
ssri
Prior art date
Application number
EA199800140A
Other languages
English (en)
Other versions
EA003775B1 (ru
Inventor
Грэхам Стэнли Леонард
Дэвид Филип Эдлер
Original Assignee
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10777960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199800140(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс
Publication of EA199800140A1 publication Critical patent/EA199800140A1/ru
Publication of EA003775B1 publication Critical patent/EA003775B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polyurethanes Or Polyureas (AREA)

Abstract

Лекарственная форма с контролируемым высвобождением или пролонгированным высвобождением включает избирательный ингибитор обратного захвата серотонина (SSRI), такой как пароксетин.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800140A 1995-07-20 1996-07-19 Композиции с контролируемым высвобождением пароксетина EA003775B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9514842.5A GB9514842D0 (en) 1995-07-20 1995-07-20 Novel formulation
PCT/EP1996/003252 WO1997003670A1 (en) 1995-07-20 1996-07-19 Paroxetine controlled release compositions

Publications (2)

Publication Number Publication Date
EA199800140A1 true EA199800140A1 (ru) 1998-10-29
EA003775B1 EA003775B1 (ru) 2003-08-28

Family

ID=10777960

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200100022A EA003508B1 (ru) 1995-07-20 1996-07-19 Композиции с контролируемым высвобождением пароксетина
EA199800140A EA003775B1 (ru) 1995-07-20 1996-07-19 Композиции с контролируемым высвобождением пароксетина

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200100022A EA003508B1 (ru) 1995-07-20 1996-07-19 Композиции с контролируемым высвобождением пароксетина

Country Status (41)

Country Link
EP (2) EP1382337A1 (ru)
JP (2) JP3922392B2 (ru)
KR (1) KR100468351B1 (ru)
CN (2) CN1117567C (ru)
AP (1) AP1052A (ru)
AR (1) AR003463A1 (ru)
AT (1) ATE253361T1 (ru)
AU (1) AU6659196A (ru)
BG (1) BG64076B1 (ru)
BR (1) BR9609857A (ru)
CA (2) CA2227298C (ru)
CY (1) CY2408B1 (ru)
CZ (1) CZ294110B6 (ru)
DE (1) DE69630603T3 (ru)
DK (1) DK0839039T4 (ru)
DZ (1) DZ2074A1 (ru)
EA (2) EA003508B1 (ru)
EG (1) EG23934A (ru)
ES (1) ES2208757T5 (ru)
GB (1) GB9514842D0 (ru)
HK (1) HK1010494A1 (ru)
HU (1) HU228853B1 (ru)
IL (1) IL122940A0 (ru)
MA (1) MA23942A1 (ru)
MX (1) MX9800571A (ru)
MY (1) MY141373A (ru)
NO (1) NO315637B1 (ru)
NZ (1) NZ315006A (ru)
OA (1) OA10652A (ru)
PE (1) PE16098A1 (ru)
PL (1) PL184987B1 (ru)
PT (1) PT839039E (ru)
RO (1) RO119119B1 (ru)
SI (1) SI0839039T2 (ru)
SK (1) SK284117B6 (ru)
TR (1) TR199800077T1 (ru)
TW (1) TW464513B (ru)
UA (1) UA68328C2 (ru)
UY (3) UY24288A1 (ru)
WO (1) WO1997003670A1 (ru)
ZA (1) ZA966148B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
EE03970B1 (et) * 1997-06-10 2003-02-17 Synthon B.V. 4-fenüülpiperidiinühend, selle valmistamine ja kasutamine ning seda sisaldav ravim
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
EA002482B1 (ru) 1997-07-01 2002-06-27 Пфайзер Инк. Соли сертралина и лекарственные формы с длительным высвобождением сертралина
GB9808479D0 (en) * 1998-04-22 1998-06-17 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
EP1161241B1 (de) 1999-03-12 2005-12-07 Aesica Pharmaceuticals Ltd. Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP1178780B1 (en) * 1999-05-20 2007-07-18 ELAN CORPORATION, Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
WO2003013480A1 (en) * 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
MXPA06004752A (es) 2003-10-29 2006-07-05 Wyeth Corp Composiciones farmaceuticas de liberacion mantenida que contienen aplindore y sus derivados.
US20050209218A1 (en) * 2004-02-13 2005-09-22 Meyerson Laurence R Methods and compositions for the treatment of psychiatric conditions
WO2005107716A1 (en) * 2004-03-25 2005-11-17 Cadila Healthcare Limited Controlled release paroxetine-containing tablets based on a core and a coating
WO2007015270A2 (en) * 2005-08-02 2007-02-08 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
WO2007132344A2 (en) * 2006-05-09 2007-11-22 Aurobindo Pharma Limited Controlled release compositions of an antidepressant agent
KR100885029B1 (ko) 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
WO2009006299A2 (en) * 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
CN101855218A (zh) 2007-09-13 2010-10-06 康塞特医药品有限公司 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成
TW201010743A (en) 2008-09-05 2010-03-16 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
PL2470166T3 (pl) * 2009-08-24 2013-11-29 H Lundbeck As Nowe kompozycje 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny
CN103371982A (zh) * 2012-04-20 2013-10-30 王进京 盐酸帕罗西汀肠溶控释片新型处方组成及制备方法
IN2015MN00005A (ru) * 2012-07-09 2015-10-16 Unilever Plc
CN103550182B (zh) * 2013-10-29 2015-04-08 吉林省东盟制药有限公司 一种肠溶缓释组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
ATE137404T1 (de) * 1990-08-21 1996-05-15 Theratech Inc Zusammensetzungen zur kontrollierten freigabe
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
AU657973B2 (en) * 1991-05-07 1995-03-30 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
JPH05139964A (ja) * 1991-11-14 1993-06-08 Takada Seiyaku Kk 塩酸メキシレチン腸溶性製剤
ES2168290T3 (es) * 1993-11-23 2002-06-16 Euro Celtique Sa Metodo para preparar una composicion de liberacion sostenida.
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
CA2216934A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release

Also Published As

Publication number Publication date
NZ315006A (en) 2000-01-28
HU228853B1 (en) 2013-06-28
NO980240D0 (no) 1998-01-19
JP3922392B2 (ja) 2007-05-30
WO1997003670A1 (en) 1997-02-06
BR9609857A (pt) 1999-03-16
EP0839039A1 (en) 1998-05-06
DE69630603T2 (de) 2004-09-23
CY2408B1 (en) 2004-09-10
EP0839039B2 (en) 2007-06-06
UY24436A1 (es) 2001-08-27
OA10652A (en) 2002-09-18
GB9514842D0 (en) 1995-09-20
CN1195986A (zh) 1998-10-14
EA003775B1 (ru) 2003-08-28
UY26242A1 (es) 2001-01-31
TR199800077T1 (xx) 1998-05-21
AU6659196A (en) 1997-02-18
NO980240L (no) 1998-01-20
SK5398A3 (en) 1998-07-08
AR003463A1 (es) 1998-08-05
IL122940A0 (en) 1998-08-16
EA200100022A1 (ru) 2001-06-25
MX9800571A (es) 1998-04-30
HUP9900299A3 (en) 1999-11-29
PL324553A1 (en) 1998-06-08
AP1052A (en) 2002-03-21
ATE253361T1 (de) 2003-11-15
HUP9900299A2 (hu) 1999-09-28
DE69630603D1 (de) 2003-12-11
SI0839039T1 (en) 2004-04-30
PE16098A1 (es) 1998-04-16
JPH11509539A (ja) 1999-08-24
BG64076B1 (bg) 2003-12-31
JP2006265258A (ja) 2006-10-05
PL184987B1 (pl) 2003-01-31
ES2208757T5 (es) 2007-12-16
CZ294110B6 (cs) 2004-10-13
DE69630603T3 (de) 2008-01-03
CA2445678C (en) 2009-11-24
EG23934A (en) 2008-01-14
UY24288A1 (es) 1997-01-16
UA68328C2 (en) 2004-08-16
AP9801177A0 (en) 1998-01-31
CA2227298A1 (en) 1997-02-06
NO315637B1 (no) 2003-10-06
SK284117B6 (sk) 2004-09-08
EP0839039B1 (en) 2003-11-05
SI0839039T2 (sl) 2007-10-31
DK0839039T3 (da) 2004-03-08
CN1282456C (zh) 2006-11-01
KR100468351B1 (ko) 2005-03-16
CA2227298C (en) 2003-12-09
DZ2074A1 (fr) 2002-07-22
EA003508B1 (ru) 2003-06-26
MY141373A (en) 2010-04-16
CA2445678A1 (en) 1997-02-06
ZA966148B (en) 1998-01-19
KR19990029076A (ko) 1999-04-15
RO119119B1 (ro) 2004-04-30
MA23942A1 (fr) 1997-04-01
CN1515257A (zh) 2004-07-28
CZ18398A3 (cs) 1998-06-17
EP1382337A1 (en) 2004-01-21
DK0839039T4 (da) 2007-10-08
TW464513B (en) 2001-11-21
BG102259A (en) 1998-09-30
ES2208757T3 (es) 2004-06-16
CN1117567C (zh) 2003-08-13
HK1010494A1 (en) 1999-06-25
PT839039E (pt) 2004-03-31

Similar Documents

Publication Publication Date Title
EA199800140A1 (ru) Композиции с контролируемым высвобождением пароксетина
NO994877L (no) Kalsilytiske forbindelser
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
DK0747050T4 (da) Farmaceutiske sammensætninger, der indeholder irbesartan
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
EA200001039A1 (ru) Кальцилитические соединения
EA200400455A1 (ru) Способ приготовления быстрорастворимой дозировочной формы
ES2171969T3 (es) Combinacion fusible de estabilizadores.
EA200100854A1 (ru) Кальций-литические соединения
NO983802L (no) Benzothiofener, formuleringer inneholdende samme og fremgangsmåter
EA200001134A1 (ru) Вакцина
EA200000112A1 (ru) Новая композиция
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
ITRM950143V0 (it) Fermo per evitare la dilatazione di contenitori comprimibili, dopo la loro compressione.
ES2157419T3 (es) Arilazadioxacicloalquenos substituidos, fungicidas.
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
ID27733A (id) Metoksiminofenilasetamida
WO2003103643A8 (en) ANTI-DEPRESSIVE ORAL ADMINISTRATION FORMULATION CONTAINING A SELECTIVE SEROTONIN REABSORPTION INHIBITOR
ATE491709T1 (de) Pyrrolidinohydrochinazoline
NO20002575D0 (no) Substituerte oksimer som neurokininantagonister
AR053675A2 (es) Composicion herbicida
ECSP961826A (es) Nueva formulacion
FI903237A0 (fi) Fenoxipyridinaminer och deras derivat, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
AR030750A1 (es) 1-amino-alquilciclohexanos como agentes tripanocidas

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM RU